(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
0.00% $ 40.01
Live Chart Being Loaded With Signals
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures...
Stats | |
---|---|
Dzisiejszy wolumen | 4.00 |
Średni wolumen | 1 120.00 |
Kapitalizacja rynkowa | 11.48B |
EPS | $9.72 ( 2023-11-06 ) |
Last Dividend | $0.603 ( 2023-03-30 ) |
Next Dividend | $0 ( N/A ) |
P/E | 39.22 |
ATR14 | $0 (0.00%) |
Eisai Co., Ltd. Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Eisai Co., Ltd. Finanse
Annual | 2023 |
Przychody: | $744.40B |
Zysk brutto: | $543.48B (73.01 %) |
EPS: | $193.31 |
FY | 2023 |
Przychody: | $744.40B |
Zysk brutto: | $543.48B (73.01 %) |
EPS: | $193.31 |
FY | 2022 |
Przychody: | $756.23B |
Zysk brutto: | $569.79B (75.35 %) |
EPS: | $167.27 |
FY | 2021 |
Przychody: | $645.94B |
Zysk brutto: | $484.63B (75.03 %) |
EPS: | $146.95 |
Financial Reports:
No articles found.
Eisai Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.555 (N/A) |
$0 (N/A) |
$0.603 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.784 | 2014-03-27 |
Last Dividend | $0.603 | 2023-03-30 |
Next Dividend | $0 | N/A |
Payout Date | 2018-05-24 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | $11.60 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.79 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.00 | |
Div. Directional Score | 7.04 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TTDKF | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
JMHLY | Ex Dividend Knight | 2023-08-16 | Semi-Annually | 0 | 0.00% | |
BNPQY | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% | |
REMYY | Ex Dividend Junior | 2023-09-26 | Annually | 0 | 0.00% | |
FBAK | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
VONOY | Ex Dividend Junior | 2023-05-26 | Annually | 0 | 0.00% | |
LNNGY | Ex Dividend Knight | 2023-08-23 | Annually | 0 | 0.00% | |
CIHKY | Ex Dividend Knight | 2023-07-03 | Annually | 0 | 0.00% | |
SGAPY | Ex Dividend Knight | 2023-08-02 | Semi-Annually | 0 | 0.00% | |
GLAPY | Ex Dividend Knight | 2023-08-25 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0606 | 1.500 | 8.79 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0346 | 1.200 | 8.85 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0546 | 1.500 | -0.504 | -0.756 | [0.1 - 1] |
payoutRatioTTM | 1.011 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 2.38 | 0.800 | 3.10 | 2.48 | [1 - 3] |
quickRatioTTM | 1.697 | 0.800 | 4.72 | 3.78 | [0.8 - 2.5] |
cashRatioTTM | 1.025 | 1.500 | 5.42 | 8.12 | [0.2 - 2] |
debtRatioTTM | 0.127 | -1.500 | 7.89 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 25.36 | 1.000 | 1.719 | 1.719 | [3 - 30] |
operatingCashFlowPerShareTTM | 215.91 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 166.26 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.203 | -1.500 | 9.19 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.789 | 1.000 | 0.176 | 0.176 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0790 | 1.000 | -0.419 | -0.419 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.372 | 1.000 | 9.04 | 9.04 | [0.2 - 2] |
assetTurnoverTTM | 0.572 | 0.800 | 9.52 | 7.62 | [0.5 - 2] |
Total Score | 10.08 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 39.99 | 1.000 | 6.06 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0546 | 2.50 | -0.324 | -0.756 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 166.26 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.0168 | 1.500 | 9.58 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 215.91 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 1.011 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0.0162 | 1.500 | -3.23 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0826 | 1.000 | -0.434 | 0 | [0.1 - 0.5] |
Total Score | 4.00 |
Eisai Co., Ltd.
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej